Report of Foreign Issuer (6-k)

Date : 05/24/2019 @ 5:04PM
Source : Edgar (US Regulatory)
Stock : Immuron Ltd (IMRN)
Quote : 3.7236  0.0736 (2.02%) @ 12:59AM

Report of Foreign Issuer (6-k)

 

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2019

 

Commission File Number: 001-38104

 

IMMURON LIMITED
(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia 3053

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. 

Form 20-F    Form 40-F 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): 

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes                      No 

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

 

- 1 -

 

 

EXPLANATORY NOTE

 

On May 23, 2019, Immuron Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the several underwriters listed therein (the “Underwriters”), with respect to the issuance and sale in an underwritten public offering (the “Offering”) by the Company of an aggregate of 500,000 American Depository Shares (“ADSs”) at a public offering price of $4.00 per ADS. Each ADS represents 40 ordinary shares, no par value per share.

 

Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 45-day option to purchase up to an additional 75,000 ADSs, solely to cover over-allotments, if any. 

 

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters and termination provisions.

 

The Offering is expected to close on May 29, 2019, subject to the satisfaction of customary closing conditions.

 

The estimated gross proceeds to the Company are expected to be approximately $2,000,000 prior to deducting underwriting discounts, commissions and other estimated offering expenses. The Company intends to use the net proceeds from the offering to support its clinical trials and its non-clinical, manufacturing and regulatory activities as well as for working capital and general corporate purposes.

 

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto is incorporated herein by reference.

 

The ADSs are offered by the Company pursuant to a registration statement on Form F-3 (File No. 333-230762) filed with the Securities and Exchange Commission (the “Commission”), which was declared effective by the Commission on April 17, 2019.

 

On May 23, 2019, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 hereto. Exhibit 99.1 shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

The legal opinion of Francis Abourizk Lightowlers, Australian counsel to the Company, relating to the legality of the issuance and sale of the ADSs is filed as Exhibit 5.1 hereto.

 

 

EXHIBITS

 

Exhibit
Number
 
Description
1.1   Form of Underwriting Agreement
5.1   Opinion of Francis Abourizk Lightowlers, Australian counsel to Immuron Limited
23.1   Consent of Francis Abourizk Lightowlers, Australian counsel to Immuron Limited (included in Exhibit 5.1)
99.1   Press Release

 

- 2 -

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  IMMURON LIMITED
   
Date:  May 24, 2019 By: /s/ Gary S. Jacob
    Gary S. Jacob
    Chief Executive Officer

 

- 3 -

 

Immuron (NASDAQ:IMRN)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Immuron Charts.

Immuron (NASDAQ:IMRN)
Intraday Stock Chart

Today : Tuesday 18 February 2020

Click Here for more Immuron Charts.

Latest IMRN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.